Insider Transactions in Q1 2024 at Kyverna Therapeutics, Inc. (KYTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2024
|
Vida Ventures, LLC |
BUY
Open market or private purchase
|
Indirect |
253,136
+50.0%
|
$5,568,992
$22.0 P/Share
|
|
Feb 12
2024
|
Vida Ventures, LLC |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Fred E Cohen |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Beth C Seidenberg |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Westlake Bio Partners Fund I, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,523,924
+50.0%
|
-
|
|
Feb 12
2024
|
Bain Capital Life Sciences Investors, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+12.45%
|
$9,900,000
$22.0 P/Share
|
|
Feb 12
2024
|
Bain Capital Life Sciences Investors, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,713,868
+50.0%
|
-
|
|
Feb 12
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
910,000
+18.07%
|
$20,020,000
$22.0 P/Share
|
|
Feb 12
2024
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,216,119
+50.0%
|
-
|
|
Feb 12
2024
|
Northpond Ventures Iii Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+50.0%
|
$9,900,000
$22.0 P/Share
|
|
Feb 12
2024
|
Northpond Ventures Iii Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,805,426
+50.0%
|
-
|